Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › ENTERO

ENTERO

Entero Healthcare Solutions Limited
Micro-capHealthcare ↗

What the six lenses say about ENTERO — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1898.4
2026-09-08
VWAP · 1Y anchor
₹1254
+51.3% from VWAP
P/E · TTM
71.8×
TTM EPS ₹26.4
52-week range
100%
position low→high
RSI(14)
86
momentum

Own sector index

Healthcare ↗
Neutral

1M

-1.1%

3M

+7.1%

1Y

+14.5%

Breadth >EMA21

55%

How ENTERO’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
5.5
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD9100›

The actual numbers

Price vs VWAP (1y)+51.3%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+51.0%
Price vs 50-EMA+30.9%
RSI(14)86
RS vs Nifty 500 · 3M+65.2%
RS vs sector · 3M+62.5%
52-week range100%
Volume vs 30d avg0.31×
Volume vs 60d avg0.51×
ATR(14) · volatility87.7
Bollinger width · vol contraction0.473
FundamentalD747›

The actual numbers

Return on equity (ROE)8.6%
Operating margin3.5%
Net margin2.2%
Revenue growth · YoY+29.4%
EPS growth · YoY+21.3%
Debt / equity0.40×

Full 8-quarter history in the financials table below.

ValuationD24›

The actual numbers

P/E (TTM)71.8×
TTM EPS₹26.4
52-week range100%
CatalystD849›

The actual numbers

Earnings & momentum38
Capital actions50
Governance86

Every filing in the corporate-announcements panel below.

FlowD240›

The actual numbers

Promoter holding52.4%
Delivery · 30d avg46.6%
Up/down-day asymmetry-1.5pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D9 + D2 ) ÷ 2 = 5.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
94
Conviction score 94/100 · avg-decile strength 5.5/10
Conviction score94/100›
TechnicalD9›
FundamentalD7›
ValuationD2›
CatalystD8›
FlowD2›

Policy

Government policy · Healthcare

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+4.4pp
+6.1pp
+56.3pp
+66.8pp
+84.2pp
+64.7pp
Nifty 500
Broad-market baseline
+4.3pp
+6.1pp
+55.2pp
+65.2pp
+78.5pp
+59.5pp
Sector
Own-sector index
—
—
+53.8pp
+62.5pp
+69.8pp
+46.2pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

ENTERO daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1898.40+70.80

Relative strength

RS vs baseline · rebased to 100

ENTERO ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
138.86+5.74

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,0971,3011,3591,3391,4041,5711,7071,910
↳ change QoQ—+18.6%+4.5%-1.5%+4.9%+11.9%+8.7%+11.9%
EBITDA (₹cr)4454584950626886
EBITDA margin4.0%4.1%4.2%3.7%3.6%4.0%4.0%4.5%
PAT (₹cr)2126293130373445
↳ change QoQ—+26.8%+13.1%+5.3%-3.2%+23.3%-8.1%+32.4%
Net margin1.9%2.0%2.2%2.3%2.1%2.4%2.0%2.4%
EPS (₹)4.625.435.855.906.397.266.356.44
D/E————————
YoY growth · Mar '26Revenue +42.6% YoYPAT +45.2% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 24 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Aug '26
    LOWgovernance
    Change in Management
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 17 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 7 Aug '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 7 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 5 Aug '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 4 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    HIGHcapital
    Acquisition
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 30 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Jul '26
    MEDIUMgovernance
    Cessation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Jun '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds ENTERO

Mutual funds holding ENTERO (10)

FundWeightAUM ₹crGrade
ICICI Pru Pharma Healthcare Diag Gr1.72%6,803
Bank of India Small Cap Reg Gr0.91%2,819
Bank of India Flexi Cap Fund Reg Gr1.77%2,786
Invesco India ELSS Tax Saver Fund Gr1.01%2,699
HSBC Consumption Reg Gr0.72%1,762
Bank of India Multi Cap Reg Gr2.62%1,259
Invesco India Agrsv HybReg Gr0.98%787
Bank of India Large & Mid Cap EcoBonus2.09%514
Bank of India Large & Mid Cap Reg Gr2.09%514
Bank of India Large & Mid Cap Reg Bns2.09%514

ETFs holding ENTERO (0)

No tracked ETF holds ENTERO ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Healthcare